lenalidomide + temsirolimus

Lenalidomide + temsirolimus is a **combination regimen** consisting of lenalidomide, an immunomodulatory and anti-angiogenic small molecule, and temsirolimus, a small molecule inhibitor of the mammalian target of rapamycin (mTOR)[1][3][4][5]. Lenalidomide acts primarily by modulating the immune system, inhibiting angiogenesis, and promoting proteasomal degradation of transcription factors involved in oncogenesis. Temsirolimus inhibits mTOR, a key component of the PI3K/Akt/mTOR pathway, reducing cell proliferation and survival. Together, these agents show **synergistic anti-cancer activity** by targeting the tumor microenvironment and signal transduction pathways with overlapping and complementary mechanisms of action. This combination has undergone phase I/II clinical trials in relapsed/refractory lymphomas, soft tissue sarcomas, adenoid cystic carcinoma, multiple myeloma, and other advanced cancers[1][2][3][4][5].

Other names

lenalidomide and temsirolimusLEN + TEMTEM/LEN